Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: A comparison of the effects exerted by roscovitine and olomoucine

Polish Journal of Pharmacology

Volumn 56, Issue 5, 2004, Pages 635-641

  Wesierska Gadek, Józefa ^a   Gueorguieva, Marieta ^a   Wojciechowski, Jacek ^a   Horky, Marcel ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

AIF release; Apoptosis; FACS analysis; G2 Marrest; MCF 7 cells; Mitochondrial dissipation; p53 up regulation; PARP 1 cleavage

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; MITOCHONDRIAL PROTEIN; OLOMOUCINE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; ROSCOVITINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MITOCHONDRIAL MEMBRANE; MITOSIS INHIBITION; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; UPREGULATION;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; HUMANS; KINETIN; PROTEIN KINASE INHIBITORS; PURINES;

EID: 12344299194     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bargonetti J, Manfredi JJ: Multiple roles of the tumor suppressor p53. Curr Opin Oncol, 2002, 14, 86-91.
2. Blagosklonny MV: P53: an ubiquitous target of anticancer drugs. Int J Cancer, 2002, 98, 161-166.
3. WAF/CIP1 and p53 and protects p21-sensitive cells from paclitaxel. Cancer Biol Ther, 2002, 1, 420-425.
4. Blagosklonny MV, Demidenko ZN, Fojo T: Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity. Cell Cycle, 2002, 1, 67-74.
5. Blagoskonny MV, Pardee AB: Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res, 2001, 61, 4301-4305.
6. David-Pfeuty D: Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor derived cells. Oncogene, 1999, 18, 7409-7422.
7. David-Pfeuty D, Nouvian-Dooghe Y, Sirri V, Roussel P, Hernandez-Verdun D: Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells. Oncogene, 2001, 20, 5951-5963.
8. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH: Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem, 1997, 243, 518-526.
9. Edamatsu H, Gau CL, Nemoto T, Guo L, Tamanoi F: Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene, 2000, 27, 3059-3068.
10. Fiskum G, Kowaltowksi AJ, Andreyev AY, Kushnareva YE, Starkov AA: Apoptosis-related activities measured with isolated mitochondria and digitonin-permeabilized cells. Methods Enzymol, 2000, 322, 222-234.
11. Gray N, Detivaud L, Doerig C, Meijer L: ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem, 1999, 6, 859-875.
12. Jänicke RU, Sprengart ML, Wati MR, Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem, 1998, 273, 9357-9360.
13. Ljungman M, Paulsen MT: The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol, 2001, 60, 785-789.
14. Lövborg H, Wojciechowski J, Larsson R, Wesierska-Gadek J: Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly(ADP-ribose)polymerase-1. Cancer Res, 2002, 62, 4206-4211.
15. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inaga M et al.: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem, 1997, 243, 527-536.
16. Mgbonyebi OP, Russo J, Russo IH: Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res, 1999, 59, 1903-1910.
17. Nurse P: Cyclin dependent kinases and cell cycle control (Nobel lecture). Chembiochem, 2002, 3, 596-603.
18. Tam SW, Shay JW, Pagano M: Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res, 1994, 54, 5816-5820.
19. Vindelov LL, Christensen IJ, Keiding N, Spang-Thomsen M, Nissen NI: Long-term storage of samples for flow cytometric DNA analysis. Cytometry, 1983, 3, 317-322.
20. Vitali L, Yakisich JS, Vita MF, Fernandez A, Settembrini L, Siden A, Cruz M et al.: Roscovitine inhibits ongoing DNA synthesis in human cervical cancer. Cancer Lett, 2002, 1, 7-12.
21. Wesierska-Gadek J, Gueorguieva M, Wojciechowski J, Horky M: Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharmacol, 2003, 55, 895-902.
22. Wesierska-Gadek J, Schloffer D, Kotala V, Horky M: Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer, 2002, 101, 128-136.
23. Wesierska-Gadek J, Schmid G: Overexpressed Poly-(ADP-ribose)polymerase delays the release of rat cells from p53-mediated G1 checkpoint. J Cell Biochem, 2000, 80, 85-103.
24. Wesierska-Gadek J, Wang Z-Q, Schmid G: Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Cancer Res, 1999, 59, 28-34.
25. Wojciechowski J, Horky M, Gueorguieva M, Wesierska-Gadek J: Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer, 2003, 106, 486-495.
26. Yakisich JS, Boethius J, Lindblom IO, Wallstedt L, Vargas VI, Siden A, Cruz MH: Inhibition of DNA synthesis in human gliomas by roscovitine. Neuroreport, 1999, 12, 2563-2567.
27. Zheng TS, Hunot S, Kuida K, Momoi T, Srinivasan A, Nicholson DW, Lazebnik Y et al.: Deficiency in caspase-9 or caspase-3 induces compensatory caspase-activation. Nat Med, 2000, 6, 1241-1247.